InMode
Morpheus8
A fractional radiofrequency device that inserts an array of electrodes into tissue and delivers RF energy at selected depths.
Fractional radiofrequency microneedlingReviewed 7/30/2026Source recorded
At a glance
| Primary purpose | Dermatologic and surgical procedures requiring electrocoagulation, hemostasis, or contraction/coagulation of soft tissue within the device's cleared parameters. |
|---|---|
| Mechanism | Programmable needle electrodes penetrate tissue and deliver fractional bipolar radiofrequency, creating discrete zones of thermal coagulation at selected depths. |
| When results appear | Early treatment effects evolve over weeks to months as healing and remodelling occur. |
| Typical sessions | Often delivered as a series, but a universal session count is not established by the FDA clearance; protocol depends on indication and settings. |
| Downtime | Redness, swelling, crusting, pinpoint bleeding, tenderness, and temporary track marks can occur; deeper or higher-energy treatment can extend recovery. |
| Reversibility | Not reversible; needle and thermal injury cannot be withdrawn. |
| Documented risks | Pain, bleeding, infection, burns, pigment change, scarring, fat loss, contour change, nerve injury, and disfigurement. FDA issued a 2025 safety communication about serious complications reported with certain RF-microneedling uses. |
| Most common disappointment | Device branding can obscure how strongly depth, energy, passes, tip, and provider judgment determine both result and risk. |
| Common marketing misconception | FDA clearance for coagulation/contraction uses is not a blanket clearance for every advertised wrinkle, scar, fat-remodelling, or tightening claim. |
| What varies by provider | Needle depth, coated versus uncoated tip, energy per pin, pulse duration, passes, overlap, treatment endpoint, anatomy, anesthesia, and infection control. |
| Skin-tone considerations | The K231790 clearance limits energy above 62 mJ per pin to Fitzpatrick skin types I–IV. Lower-energy treatment still requires individualized settings and pigment-risk counselling. |
| When this treatment may not be appropriate | When the patient cannot accept thermal-injury risks, has active infection or impaired healing, or expects a result outside the supported device indication. |
| United States regulatory status | FDA 510(k)-cleared, including K231790, for specified dermatologic and surgical electrocoagulation, hemostasis, and soft-tissue coagulation/contraction uses; high-energy use has a Fitzpatrick-type limitation. |
| Canadian regulatory status | Health Canada MDALL lists active Class III InMode fractional RF device licences that include Morpheus8 configurations; exact model and handpiece should be verified. |
| Evidence status | High for device mechanism, clearance boundaries, and current FDA safety warning; lower and heterogeneous for aesthetic protocol, session count, and durability. |
Sources
- FDA 510(k) database K231790FDA 510(k) record · regulatory-primary · supports 2 profile fields
- FDA 510(k) Summary K231790: Morpheus8FDA 510(k) summary · regulatory-primary · supports 16 profile fields
- FDA Safety Communication: Potential Risks with Certain Uses of RF MicroneedlingFDA safety communication · regulatory-primary · supports 7 profile fields
- Health Canada MDALL: InMode licencesHealth Canada MDALL · regulatory-primary
- Morpheus8 510(k) clearance summaryregulator
Related comparisons
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.